The Fellow on Call: The Heme/Onc Podcast

We are not yet done with our breast cancer series, but we could not wait to share this incredibly personal conversation with a patient with a recent breast cancer diagnosis. This week, we sit down with Kaele Leonard, who herself is a Pulmonary/Critical Care fellow at Vanderbilt University Medical Center who was diagnosed with breast cancer in her early 30s. As physicians, we don’t always get to hear what the journey through diagnosis, treatment, and follow up looks like from a patient’s perspective. We are so grateful to Dr. Leonard for opening up about this with us. Content: - The patient experience of finding out results and subsequent management - Importance of discussing fertility preservation - Financing fertility preservation - Role of “cold caps” for our patients (https://www.breastcancer.org/treatment-side-effects/hair-loss/cold-caps-scalp-cooling) - The “post-cancer crash” ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Dive into the complexities of metastatic HER2+ breast cancer. Explore the recurrence patterns associated with different subtypes and significant clinical case studies. Discover the evolution of first-line therapies, including crucial trial results supporting current standards of care. The discussion also highlights advanced treatments like TKIs and antibody-drug conjugates, alongside practical sequencing for later-line therapies. Gain insights into the promising future of treatment options as research continues to evolve.

The discussion shifts to metastatic ER+ breast cancer, emphasizing the significance of re-biopsy during disease progression. It covers treatment strategies, including endocrine therapy alongside CDK4/6 inhibitors to enhance progression-free survival. Insights on second-line targeted therapies, such as CERDs and PIK3CA inhibitors, are shared. The podcast also explores innovative approaches like antibody-drug conjugates and single-agent chemotherapy options. Key recommendations focus on prioritizing clinical trials and individualized treatment plans.

Dive into the complexities of triple-negative breast cancer (TNBC) and discover what differentiates it from other subtypes. Learn about the significance of neoadjuvant therapy and the intricacies of pathologic complete response versus residual cancer burden. Explore the latest trial data, including KEYNOTE-522, and the implications for treatment in patients with residual disease. The discussion includes practical decision-making tips for BRCA-positive patients, along with insights on chemotherapy regimens and evolving treatment algorithms.

Dive into the fascinating world of HER2+ early stage breast cancer. Discover the biology behind HER2 and the groundbreaking origins of trastuzumab. Explore the pivotal trials that highlight the survival benefits of various treatments. Learn about the innovative TCHP regimen and its impact on cardiotoxicity. Uncover management strategies for small tumors and how to approach residual disease with T-DM1. Get equipped with practical algorithms to enhance decision-making in treatment.

Dive into the evolving landscape of resectable non-small cell lung cancer (NSCLC) treatments. Discover insights from the KEYNOTE 671 trial, showcasing the benefits of combining neoadjuvant chemotherapy with immunotherapy. The hosts break down crucial statistics, including improved event-free survival and pathologic complete response rates. They also tackle complex topics like interaction tests and multiplicity in clinical trials, shedding light on their implications for practice. Tune in for a rich discussion that blends data with practical insights!

Dive into the latest in treatments for classical Hodgkin's lymphoma, exploring standard regimens and innovative immunotherapies. The hosts dissect findings from the SWOG 1826 trial, highlighting impressive one-year progression-free survival rates. They unravel the mystery of p-values and what it means when trial results say 'the median was not reached.' This engaging discussion combines medical insights with practical implications, making complex topics accessible and fascinating.

We are taking a small pause from our breast cancer series to discuss an important topic that is so critical to understand for clinical practice, no matter what discipline of medicine you are in: the fundamentals of transfusion medicine. This topic often shows up quite frequently on board exams, as well. In this episode, we talk about terms such as “type and screen” and more. Content: - What is a "type and screen"?- What does this process entail? - What is the difference between this and crossmatching? - When do we see discrepancies in the antibody screen? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Surprise! The teams at Two Onc Docs and The Fellow on Call are teaming up for his special series! Each episode will focus on a single abstract, poster, or oral presentation from ASCO 2023, and will feature a quick review of any guidelines and management pointers relevant to the disease state under study, followed by an overview of the study design and findings, and finally a discussion of the implications of the research on clinical practice.We expect to release episodes on June 12, 14, 19, 21, and 26. Episodes will be released alternating between our two podcasts, so make sure you’re subscribed to both!Follow Two Onc Docs on Twitter: www.twitter.com/twooncdocsSubscribe to Two Onc Docs on Apple Podcasts: https://podcasts.apple.com/us/podcast/two-onc-docs/id1616541733 Follow The Fellow on Call on Twitter: www.twitter.com/thefellowoncall Subscribe to The Fellow on Call on Apple Podcasts: https://podcasts.apple.com/us/podcast/the-fellow-on-call-the-heme-onc-podcast/id1602921628 Subscribe to The Fellow on Call on Spotify: https://open.spotify.com/show/3LFKY3jlU2T0MpvKwkvMvl?si=acca1fa9413a4f60&nd=1 Subscribe to The Fellow on Call on Google Podcasts: https://podcasts.google.com/search/the%20fellow%20on%20call

The hosts dive deep into the management of early stage ER+/HER2- breast cancer. They discuss who should receive chemotherapy and the relevance of gene expression assays like Oncotype and MammaPrint. Key trial results shed light on treatment distinctions based on menopausal and nodal status. The conversation also covers selecting appropriate chemotherapy regimens, the importance of survivorship care, and introduces targeted adjuvant therapies like abemaciclib for high-risk patients. It's a goldmine of insights for those navigating breast cancer treatment.